BetterLife Continues Progress on BETR-001 IND-Enabling Studies
08 juin 2023 08h00 HE
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, June 08, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
Alvotech tekur þátt í heilbrigðisráðstefnu fjárfestingabankans Jefferies
31 mai 2023 05h20 HE
|
Alvotech
Alvotech (NASDAQ First North: ALVO) tilkynnti í dag þátttöku í heilbrigðisráðstefnu Jefferies fjárfestingabankans, sem haldin verður í New York dagana 7.-9. júni nk. Alvotech mun halda kynningu og...
Alvotech to Participate in Jefferies Healthcare Conference
31 mai 2023 05h20 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
Alvotech og Advanz Pharma auka samstarfið með fyrirhugaðri markaðssetningu fimm líftæknilyfjahliðstæða í Evrópu
24 mai 2023 05h00 HE
|
Alvotech
Advanz Pharma öðlast með samningnum einkarétt til markaðssetningar í Evrópu á fimm fyrirhuguðum líftæknilyfjahliðstæðum Alvotech Samkomulagið nær til fyrirhugaðra hliðstæða við Simponi (golimumab) og...
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
24 mai 2023 05h00 HE
|
Alvotech
Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in EuropeThe agreement includes proposed biosimilars to Simponi® (golimumab), Entyvio® (vedolizumab) and...
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
24 mai 2023 05h00 HE
|
Alvotech
Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in EuropeThe agreement includes proposed biosimilars to Simponi® (golimumab), Entyvio® (vedolizumab) and...
Alvotech birtir uppgjör fyrir fyrstu þrjá mánuði ársins 2023 og kynnir nýjustu áfanga í rekstri félagsins
19 mai 2023 05h00 HE
|
Alvotech
Tekjur á fyrsta fjórðungi ársins jukust samanborið við sama tímabil í fyrra, úr 0,8 milljónum dollara í 15,9 milljónir dollaraFimmta lyf Alvotech hefur verið tekið til klínískra rannsókna á...
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
19 mai 2023 05h00 HE
|
Alvotech
Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022Confirmatory patient study for AVT05, a proposed biosimilar for Simponi®...
Alvotech tekur þátt í ráðstefnu fjárfestingabankans Morgan Stanley um sjálfbærar fjárfestingar
17 mai 2023 05h00 HE
|
Alvotech
Alvotech (NASDAQ First North: ALVO) tilkynnti í dag um þátttöku í fyrstu árlegu ráðstefnu fjárfestingabankans Morgan Stanley um sjálfbærar fjárfestingar, þann 22. maí nk. Fulltrúar Alvotech sitja...
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
17 mai 2023 05h00 HE
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan...